(3R,4R)-3-hydroxy-4-[4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl]-piperidine-1-carboxylic acid tert-butyl ester | 257938-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3R,4R)-3-hydroxy-4-[4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl]-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl (3R,4R)-3-hydroxy-4-{4-[3-(2-methoxybenzyloxy)-propoxy]phenyl}piperidine-1-carboxylate；tert-butyl (3R,4R)-3-hydroxy-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]piperidine-1-carboxylate
• CAS: 257938-68-4
• 化学式: C₂₇H₃₇NO₆
• 分子量: 471.594
• InChiKey: WEPZPAGVKNVUEA-RPWUZVMVSA-N

物化性质

• 沸点：
  593.8±50.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  77.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (3R,4R)-3-hydroxy-4-[4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl]-piperidine-1-carboxylic acid tert-butyl ester 在 sodium tetrahydroborate 、 sodium hydride 、 nickel dichloride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.0h， 生成 (3R,4R)-4-[4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl]-3-(1,2,3,4-tetrahydro-quinolin-7-ylmethoxy)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Piperidine renin inhibitors: from leads to drug candidates

  摘要：

  Non-peptidomimetic renin inhibitors of the piperidine type represent a novel structural class of compounds potentially free of the drawbacks seen with peptidomimetic compounds so far. Synthetic optimization in two structural series focusing on improvement of potency, as well as on physicochemical properties and metabolic stability, has led to the identification of two candidate compounds 14 and 23. Both display potent and long-lasting blood pressure lowering effects in conscious sodium-depleted marmoset monkeys and double transgenic rats harboring both the human angiotensinogen and the human renin genes. In addition, 14 normalizes albuminuria and kidney tissue damage in these rats when given over a period of 4 weeks. These data suggest that treatment of chronic renal failure patients with a renin inhibitor might result in a significant improvement of the disease status. (C) 2001 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(01)01004-7
• 作为产物：
  描述：

  (3R,4R)-4-(4-benzyloxy-phenyl)-1-((R)-1-phenyl-ethyl)-piperidin-3-ol 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 84.0h， 生成 (3R,4R)-3-hydroxy-4-[4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl]-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Piperidine renin inhibitors: from leads to drug candidates

  摘要：

  Non-peptidomimetic renin inhibitors of the piperidine type represent a novel structural class of compounds potentially free of the drawbacks seen with peptidomimetic compounds so far. Synthetic optimization in two structural series focusing on improvement of potency, as well as on physicochemical properties and metabolic stability, has led to the identification of two candidate compounds 14 and 23. Both display potent and long-lasting blood pressure lowering effects in conscious sodium-depleted marmoset monkeys and double transgenic rats harboring both the human angiotensinogen and the human renin genes. In addition, 14 normalizes albuminuria and kidney tissue damage in these rats when given over a period of 4 weeks. These data suggest that treatment of chronic renal failure patients with a renin inhibitor might result in a significant improvement of the disease status. (C) 2001 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(01)01004-7

文献信息

• Process and intermediates for preparation of substituted piperidines
  申请人：Hoffmann-La Roche Inc.

  公开号：US06274735B1

  公开（公告）日：2001-08-14

  The present invention concerns intermediates useful in and a process for the preparation of a compound of formula 1 or a salt thereof comprising a) hydroboration of a compound of formula 2 A, R1 and R2 are as herein defined. These compounds are useful in the synthesis of renin inhibitors.

  本发明涉及在制备化合物1或其盐的过程中有用的中间体和方法，包括a) 对化合物2进行氢硼化反应，其中A、R1和R2如本文所定义。这些化合物在合成肾素抑制剂中很有用。
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：SPEEDEL EXPERIMENTA AG

  公开号：WO2005061457A1

  公开（公告）日：2005-07-07

  Novel substituted piperidines of the general formulae (I) and (II) with the substituent definitions as explained in detail in the description are described. The compounds are suitable in particular as renin inhibitors and are highly potent.

  描述了一种具有一般式(I)和(II)的新型替代哌啶化合物，其中详细说明了取代基定义。这些化合物特别适用作为肾素抑制剂，并且具有很高的效力。
• Piperidine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06197959B1

  公开（公告）日：2001-03-06

  Compounds of formula (I) wherein R1 and R2 are as defined in the description and claims and pharmaceutically acceptable salts thereof, are useful for the treating diseases associated with restenosis, glaucoma, cardiac infarct, high blood pressure and end organ damage, for example, cardiac insufficiency and kidney insufficiency.

  式(I)中的化合物，其中R1和R2如描述和索赔中定义，并且其药学上可接受的盐，对于治疗与再狭窄、青光眼、心脏梗死、高血压和器官损伤相关的疾病是有用的，例如，心脏功能不全和肾功能不全。
• Process for the production of substituted 3-hydroxypiperidines
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0979819A1

  公开（公告）日：2000-02-16

  The present invention concerns a process for the preparation of a compound of formula 1 or a salt thereof characterised in that the process comprises a) hydroboration of a compound of formula 2 in which formulae A is arylene; R1 is -C*R3R4R5; R2 is -O-alkyl, -O-cycloalkyl, -O-alkenyl, -O-aryl, -O-aralkyl, -O-aralkoxyalkyl, -O-alkylsulfonyl, -O-arylsulfonyl, chlorine, bromine or iodine; R3 is hydrogen; R4 is aryl; R5 is alkyl, cycloalkyl, aryl, alkoxyalkyl or hydroxyalkyl; and wherein C* is an asymmetric carbon atom; b) optionally followed by isolation of the desired stereoisomer.

  本发明涉及一种制备式 1 化合物或其盐的工艺 其特征在于该工艺包括 a) 式 2 化合物的硼氢化反应 其中式 A 为芳基；R1 为-C*R3R4R5；R2 为-O-烷基、-O-环烷基、-O-烯基、-O-芳基、-O-芳烷基、-O-芳烷氧基烷基、-O-烷基磺酰基、-O-芳基磺酰基、氯、溴或碘；R3 为氢；R4 为芳基；R5 为烷基、环烷基、芳基、烷氧基烷基或羟基烷基；且其中 C* 为不对称碳原子； b) 随后可选择分离出所需的立体异构体。
• RENIN INHIBITORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1180103B1

  公开（公告）日：2007-05-30